No connection

Search Results

INCR vs NSYS

INCR
InterCure Ltd.
BEARISH
Price
$0.76
Market Cap
$41.7M
Sector
Healthcare
AI Confidence
85%
NSYS
Nortech Systems Incorporated
NEUTRAL
Price
$14.48
Market Cap
$40.3M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
INCR
--
NSYS
--
Forward P/E
INCR
-0.52
NSYS
--
P/B Ratio
INCR
0.1
NSYS
1.18
P/S Ratio
INCR
--
NSYS
0.34
EV/EBITDA
INCR
--
NSYS
21.22

Profitability

Gross Margin
INCR
16.71%
NSYS
15.21%
Operating Margin
INCR
0.0%
NSYS
2.97%
Profit Margin
INCR
-29.18%
NSYS
-0.21%
ROE
INCR
-16.68%
NSYS
-0.73%
ROA
INCR
-7.74%
NSYS
1.07%

Growth

Revenue Growth
INCR
3.4%
NSYS
5.9%
Earnings Growth
INCR
--
NSYS
--

Financial Health

Debt/Equity
INCR
0.41
NSYS
0.45
Current Ratio
INCR
1.85
NSYS
1.88
Quick Ratio
INCR
1.08
NSYS
1.13

Dividends

Dividend Yield
INCR
--
NSYS
--
Payout Ratio
INCR
0.0%
NSYS
0.0%

AI Verdict

INCR BEARISH

InterCure Ltd. exhibits severe financial distress as evidenced by a weak Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. Despite a very low Price-to-Book ratio of 0.10, the company is trapped in a catastrophic long-term price decline, losing over 91% of its value over five years. Negative profit margins and crashing EPS growth suggest that the low valuation is a value trap rather than a bargain. The lack of analyst coverage and a 0/100 technical trend further reinforce a bearish outlook.

Strengths
Low Debt-to-Equity ratio (0.41) suggests manageable leverage
Current Ratio of 1.85 indicates adequate short-term liquidity
Positive Gross Margin (16.71%) shows core product viability
Risks
Severe operational weakness indicated by Piotroski F-Score of 2/9
Negative profit margins (-29.17%) and negative ROE (-16.68%)
Catastrophic price performance (-91.7% over 5 years)
NSYS NEUTRAL

NSYS exhibits a severe disconnect between its fundamental health and recent price action. The Piotroski F-Score of 2/9 indicates weak operational efficiency and financial deterioration, yet the stock is trading near its 52-week high with significant 1-year gains (+82.1%). While valuation metrics like Price/Sales (0.34) and Price/Book (1.18) suggest the company is undervalued relative to its assets and revenue, the thin profit margins and sluggish growth (5.9%) provide little fundamental support for the current price surge.

Strengths
Very low Price-to-Sales ratio (0.34) suggesting deep value
Strong liquidity with a Current Ratio of 1.88
Manageable leverage with a Debt/Equity ratio of 0.45
Risks
Critically low Piotroski F-Score (2/9) signaling poor financial health
Very thin gross margins (15.21%) for the medical device industry
Stagnant revenue growth (5.9%) compared to healthcare sector averages

Compare Another Pair

INCR vs NSYS: Head-to-Head Comparison

This page compares InterCure Ltd. (INCR) and Nortech Systems Incorporated (NSYS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile